Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback